GLP-1 & Incretin Science

What Open-Label Does to a Weight-Loss Trial

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

REDEFINE 4 was randomised but open-label: its ClinicalTrials.gov record lists masking as none. Knowing which drug you received can influence adherence, behaviour and adverse event reporting, which matters more for a behaviourally sensitive outcome like body weight than for a hard endpoint.

Key facts

REDEFINE 4 allocation
Randomised
REDEFINE 4 masking
None (open-label)
Registration
NCT06131437
Randomisation protects
Comparability at baseline
Blinding protects
What happens afterwards
Most vulnerable outcomes
Behaviourally influenced ones

Two different protections

Randomisation and blinding do different jobs and are frequently confused. Randomisation makes groups comparable at the start by distributing known and unknown differences by chance. Blinding protects what happens after that: how participants behave, how investigators assess, how adverse events get reported. A trial can have one without the other, and REDEFINE 4 did.

Why weight is a vulnerable endpoint

Body weight responds to behaviour. A participant who knows they received the drug they hoped for may adhere differently, eat differently, or persist through early side effects that would otherwise have caused them to stop. None of that requires anyone to act in bad faith. It is ordinary human response to information, and blinding exists to remove it.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Where it shows up in the numbers

Most visibly in discontinuation, which then propagates into the treatment-policy estimand. If knowledge of assignment affects who stops and when, it affects the estimand that counts everyone regardless of adherence. That is one plausible contributor to the gap between REDEFINE 4's two reported estimands, though a gap would exist in a blinded trial too.

Why it is sometimes unavoidable

Blinding two injectables with different administration schedules, devices and side-effect profiles is difficult. Participants often work out their assignment from the experience regardless of packaging. Running open-label is frequently a practical decision rather than a careless one, which is a reason to note the limitation, not to dismiss the trial.

The pattern across recent incretin evidence

REDEFINE 4 was open-label. The survodutide dose-response trial in Diabetologia carried an open-label semaglutide arm. Where a comparator is unblinded, the comparison is weaker than a fully blinded one, and that qualification belongs beside the numbers rather than in a limitations paragraph nobody reads.

How to check

The ClinicalTrials.gov record states allocation and masking directly. For NCT06131437 it reads randomised, masking none. It takes seconds and it is more reliable than a press release, which will rarely lead with the design limitation.

Frequently asked questions

Was REDEFINE 4 randomised?

Yes, randomised but open-label. Its registry record lists allocation as randomised and masking as none.

Why does blinding matter more for weight than for other endpoints?

Weight responds to behaviour, and knowing your assignment can change adherence, persistence through side effects and reporting.

Does open-label mean the trial is unreliable?

No. It is a real limitation that weakens the comparison, and blinding two different injectables is difficult.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.